226 related articles for article (PubMed ID: 26216350)
1. MicroRNAs in Ovarian Cancer.
Katz B; Tropé CG; Reich R; Davidson B
Hum Pathol; 2015 Sep; 46(9):1245-56. PubMed ID: 26216350
[TBL] [Abstract][Full Text] [Related]
2. The clinical and diagnostic role of microRNAs in ovarian carcinoma.
Davidson B; Tropé CG; Reich R
Gynecol Oncol; 2014 Jun; 133(3):640-6. PubMed ID: 24713546
[TBL] [Abstract][Full Text] [Related]
3. MicroRNAs as prognostic markers in ovarian cancer.
Llauradó M; Majem B; Altadill T; Lanau L; Castellví J; Sánchez-Iglesias JL; Cabrera S; De la Torre J; Díaz-Feijoo B; Pérez-Benavente A; Colás E; Olivan M; Doll A; Alameda F; Matias-Guiu X; Moreno-Bueno G; Carey MS; Del Campo JM; Gil-Moreno A; Reventós J; Rigau M
Mol Cell Endocrinol; 2014 Jun; 390(1-2):73-84. PubMed ID: 24747602
[TBL] [Abstract][Full Text] [Related]
4. Differential role of microRNAs in prognosis, diagnosis, and therapy of ovarian cancer.
Mahdian-Shakib A; Dorostkar R; Tat M; Hashemzadeh MS; Saidi N
Biomed Pharmacother; 2016 Dec; 84():592-600. PubMed ID: 27694003
[TBL] [Abstract][Full Text] [Related]
5. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.
Leskelä S; Leandro-García LJ; Mendiola M; Barriuso J; Inglada-Pérez L; Muñoz I; Martínez-Delgado B; Redondo A; de Santiago J; Robledo M; Hardisson D; Rodríguez-Antona C
Endocr Relat Cancer; 2011 Feb; 18(1):85-95. PubMed ID: 21051560
[TBL] [Abstract][Full Text] [Related]
6. miR-335 represents an independent prognostic marker in epithelial ovarian cancer.
Cao J; Cai J; Huang D; Han Q; Chen Y; Yang Q; Yang C; Kuang Y; Li D; Wang Z
Am J Clin Pathol; 2014 Mar; 141(3):437-42. PubMed ID: 24515774
[TBL] [Abstract][Full Text] [Related]
7. Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications.
Mezzanzanica D; Bagnoli M; De Cecco L; Valeri B; Canevari S
Int J Biochem Cell Biol; 2010 Aug; 42(8):1262-72. PubMed ID: 20035894
[TBL] [Abstract][Full Text] [Related]
8. A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer.
Hu X; Macdonald DM; Huettner PC; Feng Z; El Naqa IM; Schwarz JK; Mutch DG; Grigsby PW; Powell SN; Wang X
Gynecol Oncol; 2009 Sep; 114(3):457-64. PubMed ID: 19501389
[TBL] [Abstract][Full Text] [Related]
9. Characterization of microRNA expression in serous ovarian carcinoma.
Li Y; Yao L; Liu F; Hong J; Chen L; Zhang B; Zhang W
Int J Mol Med; 2014 Aug; 34(2):491-8. PubMed ID: 24939816
[TBL] [Abstract][Full Text] [Related]
10. MicroRNAs in ovarian cancer biology and therapy resistance.
van Jaarsveld MT; Helleman J; Berns EM; Wiemer EA
Int J Biochem Cell Biol; 2010 Aug; 42(8):1282-90. PubMed ID: 20083225
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of dicer expression in ovarian cancer tissues.
Pampalakis G; Diamandis EP; Katsaros D; Sotiropoulou G
Clin Biochem; 2010 Feb; 43(3):324-7. PubMed ID: 19782670
[TBL] [Abstract][Full Text] [Related]
12. Role of microRNAs in cancers of the female reproductive tract: insights from recent clinical and experimental discovery studies.
Logan M; Hawkins SM
Clin Sci (Lond); 2015 Feb; 128(3):153-80. PubMed ID: 25294164
[TBL] [Abstract][Full Text] [Related]
13. Recently identified drug resistance biomarkers in ovarian cancer.
Davidson B
Expert Rev Mol Diagn; 2016; 16(5):569-78. PubMed ID: 26895188
[TBL] [Abstract][Full Text] [Related]
14. The role of microRNAs in melanoma.
Luo C; Weber CE; Osen W; Bosserhoff AK; Eichmüller SB
Eur J Cell Biol; 2014; 93(1-2):11-22. PubMed ID: 24602414
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA and Long Non-Coding RNA in Ovarian Carcinoma: Translational Insights and Potential Clinical Applications.
Ma Y; Lu Y; Lu B
Cancer Invest; 2016 Oct; 34(9):465-476. PubMed ID: 27673409
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of Dicer expression in ovarian cancer-link to global microRNA changes and oestrogen receptor expression.
Faggad A; Budczies J; Tchernitsa O; Darb-Esfahani S; Sehouli J; Müller BM; Wirtz R; Chekerov R; Weichert W; Sinn B; Mucha C; Elwali NE; Schäfer R; Dietel M; Denkert C
J Pathol; 2010 Feb; 220(3):382-91. PubMed ID: 19960504
[TBL] [Abstract][Full Text] [Related]
17. [microRNA: new diagnostic and therapeutic tools in liver disease?].
Gougelet A; Colnot S
Med Sci (Paris); 2013 Oct; 29(10):861-7. PubMed ID: 24148124
[TBL] [Abstract][Full Text] [Related]
18. MicroRNAs in ovarian carcinomas.
Dahiya N; Morin PJ
Endocr Relat Cancer; 2010 Mar; 17(1):F77-89. PubMed ID: 19903743
[TBL] [Abstract][Full Text] [Related]
19. A novel serum microRNA panel to discriminate benign from malignant ovarian disease.
Langhe R; Norris L; Saadeh FA; Blackshields G; Varley R; Harrison A; Gleeson N; Spillane C; Martin C; O'Donnell DM; D'Arcy T; O'Leary J; O'Toole S
Cancer Lett; 2015 Jan; 356(2 Pt B):628-36. PubMed ID: 25451316
[TBL] [Abstract][Full Text] [Related]
20. miRNAs and ovarian cancer: An overview.
Deb B; Uddin A; Chakraborty S
J Cell Physiol; 2018 May; 233(5):3846-3854. PubMed ID: 28703277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
